Clinical Trial Update: Phase IIT Trial of SNA014 [EARLY_Phase 1]

View source ↗

Summary

Early-phase trial update for SNA014 by SmartNuclide Biopharma targeting gastric and gastroesophageal junction adenocarcinomas; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer
• Pancreatic Cancer

Drugs mentioned

• SNA014

Snippet

Sponsor: SmartNuclide Biopharma | Conditions: Adenocarcinoma of the Stomach, Adenocarcinoma of GE Junction | EARLY_Phase 1 | Status: NOT_YET_RECRUITING